文献速递消化系统肿瘤

口服避孕药使用与肝癌风险:一项基于人群的研究、系统综述与荟萃分析

Oral contraceptive use and risk of liver cancer: a population-based study, systematic review, and meta-analysis.
PubMed 文献 · Lancet Oncol · 2025-07-03

该研究基于英国百万女性研究和英国生物银行两个大型前瞻性队列,并系统综述与荟萃分析23项观察性研究。两个队列均未发现曾用与从未使用口服避孕药与肝癌风险存在关联;荟萃分析显示总体无关联,但每使用5年肝癌风险略有增加,且残余混杂不能排除。

要点

  • 百万女性研究中曾用与从未使用口服避孕药与肝癌风险无关联(HR 1.05,95%CI 0.97-1.13;p=0.27)。
  • 英国生物银行中同样无关联(HR 1.08,95%CI 0.76-1.55;p=0.66)。
  • 荟萃分析每使用5年口服避孕药肝癌风险略有增加(RR 1.06,95%CI 1.02-1.10),但残余混杂不能排除。

核心结论

  • 总体观察性研究提示曾用与从未使用口服避孕药与肝癌风险无关联。
  • 按使用时长分析,与全部肝癌或其两种主要亚型的关联很小或没有。
  • 使用时间较长时肝癌风险可能略有增加,但不能排除残余混杂。

研究设计与样本

  • 基于人群的研究,使用百万女性研究(MWS)和英国生物银行两个队列数据,纳入基线无现患癌症(非黑色素瘤皮肤癌除外)且有口服避孕药使用数据的女性。
  • 通过链接英国国家医疗服务体系癌症登记确定 Incident 肝癌诊断。
  • 采用多变量Cox比例风险回归计算风险比(HR)和95%CI。
  • 系统综述与荟萃分析检索PubMed、Embase、CINAHL Plus、Web of Science和Scopus自建库至2024年6月28日的观察性研究,采用固定效应模型合并。
  • PROSPERO注册号CRD42024552518。

主要发现

  • 百万女性研究队列1,305,024名参与者中2,765名(0.21%)发生肝癌,中位随访21.4年(IQR 18.4-22.4)。
  • 英国生物银行队列253,408名参与者中191名(0.08%)发生肝癌,中位随访12.6年(IQR 11.8-13.4)。
  • 百万女性研究中曾用与从未使用口服避孕药与肝癌风险无关联(HR 1.05,95%CI 0.97-1.13;p=0.27)。
  • 英国生物银行中曾用与从未使用口服避孕药与肝癌风险无关联(HR 1.08,95%CI 0.76-1.55;p=0.66)。
  • 23项观察性研究(含5,422例肝癌个体)的荟萃分析显示曾用与从未使用口服避孕药与肝癌无关联证据(RR 1.04,95%CI 0.98-1.11;I²=45.9%,p=0.0080)。

局限性

  • 不能排除残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oral contraceptive use has been suggested to increase the risk of liver cancer. Although the International Agency for Research on Cancer concluded in 1999 that there was sufficient evidence of an association, this was based on case-control studies with few liver cancer cases. We aimed to provide more robust epidemiological evidence on this association by analysing data from two large prospective UK cohorts and additionally conducting a systematic review and meta-analysis of previous observational studies. METHODS: In our population-based study, the relationship between oral contraceptive use and liver cancer risk was examined using data from the Million Women Study (MWS) and the UK Biobank. We included women from both cohorts who did not have a prevalent cancer at baseline (except non-melanoma skin cancer) and had provided data on oral contraceptive use; incident liver cancer diagnoses were determined using linkage to National Health Service cancer registries. We compared risk in women who had ever used oral contraceptives with women who had never used oral contraceptives. Multivariable Cox proportional hazards regression was used to calculate hazard ratios (HRs) and 95% CIs. For the systematic review and meta-analysis, we searched PubMed, Embase, CINAHL Plus, Web of Science, and Scopus from database inception to June 28, 2024, for existing observational studies. Study-specific log odds ratios (ORs) or log HRs were pooled and we determined the relative risk (RR) between oral contraceptive use and liver cancer across all studies using a fixed-effects model (PROSPERO number CRD42024552518). FINDINGS: A total of 2765 (0·21%) of 1 305 024 participants developed liver cancer in the MWS cohort (median follow-up 21·4 years; IQR 18·4-22·4) and 191 (0·08%) of 253 408 participants developed liver cancer in the UK Biobank (median follow-up 12·6 years; IQR 11·8-13·4). No association was observed between ever versus never use of oral contraceptives and liver cancer risk in either the MWS (HR 1·05, 95% CI 0·97-1·13; p=0·27) or the UK Biobank (1·08, 0·76-1·55; p=0·66). The meta-analysis of 23 observational studies, which included 5422 individuals with liver cancer, found no evidence of an association between ever versus never oral contraceptive use and liver cancer (RR 1·04, 0·98-1·11; I2 45·9%, p=0·0080). In the meta-analysis of duration of oral contraceptive use, there was a slightly increased risk of liver cancer per 5 years of use of oral contraceptives (RR 1·06, 1·02-1·10; I2 63·9%, p<0·0001), with corresponding subtype-specific RRs of 1·07 (1·00-1·14) for hepatocellular carcinoma and 1·06 (1·01-1·11) for intrahepatic cholangiocarcinoma (pheterogeneity=0·82). INTERPRETATION: The totality of observational studies suggests there is no association between ever versus never use of oral contraceptive and liver cancer risk. When looking at associations by duration of oral contraceptive use, there was little or no association with all liver cancer or its two main subtypes. There might be a small increased risk of liver cancer with longer duration of use, but residual confounding cannot be ruled out. FUNDING: Canadian Institutes of Health Research, National Institutes of Health Intramural Program, and Cancer Research UK.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Watling CZ, Sweetland S, Wojt A, et al. Oral contraceptive use and risk of liver cancer: a population-based study, systematic review, and meta-analysis. Lancet Oncol. 2025. PMID: 40617239. doi:10.1016/S1470-2045(25)00222-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。